Contrasts between the effects of zinc-α2-glycoprotein, a putative β3/2-adrenoceptor agonist and the β3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice

Journal of Endocrinology

Volumn 216, Issue 2, 2013, Pages 157-168

  Wargent, Edward T ^a   O'Dowd, Jacqueline F ^a   Zaibi, Mohamed S ^a   Gao, Dan ^b   Bing, Chen ^b   Trayhurn, Paul ^a,b   Cawthorne, Michael A ^a   Arch, Jonathan R S ^a   Stocker, Claire J ^a  

^a UNIVERSITY OF BUCKINGHAM   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

3 adrenoceptor agonist; BRL35135; Glucose tolerance; Ob ob mice; Obesity; Thermogenesis; Zinc 2 glycoprotein

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; FATTY ACID; GLUCOSE; GLYCEROL; INSULIN; MESSENGER RNA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; ZINC ALPHA2 GLYCOPROTEIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN; PHENETHYLAMINE DERIVATIVE; SEMINAL PLASMA PROTEIN; ZN ALPHA 2 GLYCOPROTEIN; ZN-ALPHA-2-GLYCOPROTEIN;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CONTROLLED STUDY; DRUG ACTIVITY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; GLYCEROL BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOLYSIS; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RNA ISOLATION; THERMOGENESIS; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; C57BL MOUSE; DRUG EFFECT; EATING; ENERGY METABOLISM; GENETICS; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADIPOSE TISSUE; ADRENERGIC BETA-AGONISTS; ANIMALS; BODY COMPOSITION; BODY WEIGHT; EATING; ENERGY METABOLISM; ION CHANNELS; LIPOLYSIS; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; OBESITY; PHENETHYLAMINES; REAL-TIME POLYMERASE CHAIN REACTION; SEMINAL PLASMA PROTEINS; THERMOGENESIS;

MLCS; MLOWN;

EID: 84874764637     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0402     Document Type: Article

References (59)

1. 3-Adrenoceptor agonists: potential, pitfalls and progress. European Journal of Pharmacology 440 99-107. (doi:10.1016/S0014-2999(02)01421-8)
2. 3-adrenoceptor agonists. Naunyn-Schmiedeberg's Archives of Pharmacology 378 225-240. (doi:10.1007/s00210-008-0271-1)
3. 3-adrenoceptor agonist drug development. Therapeutic Advances in Endocrinology and Metabolism 2 59-64. (doi:10.1177/2042018811398517)
4. Arch JR 2011b Thermogenesis and related metabolic targets in anti-diabetic therapy. Handbook of Experimental Pharmacology 201-255.
5. 3 and atypical β-adrenoceptors. Medicinal Research Reviews 13 663-729. (doi:10.1002/med.2610130604)
6. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C & Wilson S 1984 Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309 163-165. (doi:10.1038/309163a0)
7. Arch JRS, Cawthorne MA, Coney KA, Gusterson BA, Piercy V, Sennitt MV, Smith SA, Wallace J & Wilson S 1991 β-Adrenoceptor-mediated control of thermogenesis, body composition and glucose homeostasis. In Obesity and Cachexia, pp 241-268. Eds NJ Rothwell & MJ Stock. Chichester: Wiley.
8. Arch JRS, Bywater RJ, Coney KA, Ellis RDM, Thurlby PL, Smith SA & Zed C 1995 β-Adrenoceptor-mediated control of thermogenesis, body composition and glucose homeostasis. In Hormones, Thermogenesis and Obesity, pp 465-476. Eds H Lardy & F Stratman. Amsterdam: Elsevier Science Publishing Co.
9. Beaton JR, Szlavko AJ & Stevenson JA 1964 Extraction and chemical characteristics of anorexigenic and fat-mobilizing substances from rat urine. Canadian Journal of Physiology and Pharmacology 42 647-655. (doi:10.1139/y64-071)
10. Bing C, Hopkins D, Wang Q, Frankish H, Buckingham R & Williams G 1998 Direct stimulation of BAT thermogenesis does not affect hypothalamic neuropeptide Y. Peptides 19 167-170. (doi:10.1016/S0196-9781(97) 00272-6)
11. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ & Trayhurn P 2004 Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. PNAS 101 2500-5. (doi:10.1073/pnas.0308647100)
12. 2-glycoprotein: an adipokine modulator of body fat mass? International Journal of Obesity 34 1559-1565. (doi:10.1038/ijo.2010.105)
13. 1-Adrenoceptor antagonist properties of CGP 12177A and other β-adrenoceptor ligands: evidence against β(3)- or atypical β-adrenoceptors in rat aorta. British Journal of Pharmacology 142 781-787. (doi:10.1038/sj.bjp. 0705840)
14. 3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. British Journal of Pharmacology 146 679-691. (doi:10.1038/sj.bjp.0706369)
15. Carlisle HJ & Stock MJ 1993 Thermoregulatory responses to β-adrenergic agonists at low ambient temperatures in the rat. Experimental Physiology 78 775-786.
16. Cawthorne MA, Sennitt MV, Arch JR & Smith SA 1992 BRL 35135, a potent and selective atypical β-adrenoceptor agonist. American Journal of Clinical Nutrition 55 252S-257S.
17. 2-glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. Journal of Clinical Endocrinology and Metabolism 94 5062-5069. (doi:10.1210/jc. 2009-0764)
18. Gao D, Trayhurn P & Bing C 2010 Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes. Molecular and Cellular Endocrinology 325 135-142. (doi:10.1016/j.mce.2010.05.020)
19. 3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. Diabetes 49 1910-1916. (doi:10.2337/diabetes.49.11.1910)
20. Granneman JG, Burnazi M, Zhu Z & Schwamb LA 2003 White adipose tissue contributes to UCP1-independent thermogenesis. American Journal of Physiology. Endocrinology and Metabolism 285 E1230-E1236. (doi:10.1152/ajpendo.00197.2003)
21. Hashimoto K, Nagao Y, Ida K, Takeda M, Murakami N, Kato K & Mizota M 1996 Improvement of metabolic disorders and visceral fat obesity by the β 3-adrenoceptor agonist (R* R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents. Biochemical Pharmacology 52 1529-1535. (doi:10.1016/S0006-2952(96)00552-7)
22. Hirai K, Hussey HJ, Barber MD, Price SA & Tisdale MJ 1998 Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Research 58 2359-2365.
23. Hollenga C, Haas M, Deinum JT & Zaagsma J 1990 Discrepancies in lipolytic activities induced by β-adrenoceptor agonists in human and rat adipocytes. Hormone and Metabolic Research 22 17-21. (doi:10.1055/ s-2007-1004839)
24. Holloway BR, Howe R, Rao BS, Stribling D, Mayers RM, Briscoe MG & Jackson JM 1991 ICI D7114 a novel selective β-adrenoceptor agonist selectively stimulates brown fat and increases whole-body oxygen consumption. British Journal of Pharmacology 104 97-104. (doi:10.1111/ j.1476-5381.1991.tb12391.x)
25. 3-adrenergic stimulation. American Journal of Physiology. Endocrinology and Metabolism 290 E1014-E1021. (doi:10.1152/ajpendo.00105.2005)
26. Islam-Ali B, Khan S, Price SA & Tisdale MJ 2001 Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). British Journal of Cancer 85 758-763. (doi:10.1054/bjoc. 2001.1992)
27. Kekwick A & Pawan GL 1967 Fat mobilizing substance (FMS). Metabolism 16 787-796. (doi:10.1016/0026-0495(67)90181-3)
28. Kenakin TP 1984 The classification of drugs and drug receptors in isolated tissues. Pharmacological Reviews 36 165-222.
29. Kubota Y, Nakahara T, Yunoki M, Mitani A, Maruko T, Sakamoto K & Ishii K 2002 Inhibitory mechanism of BRL37344 on muscarinic receptormediated contractions of the rat urinary bladder smooth muscle. Naunyn-Schmiedeberg's Archives of Pharmacology 366 198-203. (doi:10.1007/s00210-002-0602-6)
30. Lafontan M & Berlan M 1993 Fat cell adrenergic receptors and the control of white and brown fat cell function. Journal of Lipid Research 34 1057-1091.
31. 3-adrenoceptor agonist (CL 316,243). Drug Development Research 32 69-76. (doi:10.1002/ddr. 430320203)
32. 3-adrenoceptor ligands in rat pulmonary artery. Naunyn-Schmiedeberg's Archives of Pharmacology 371 535-539. (doi:10.1007/s00210-005-1067-1)
33. 3-selective antagonists, aryloxypropanolaminotetralins. British Journal of Pharmacology 117 435-442. (doi:10.1111/j.1476-5381.1996.tb15209.x)
34. Marrades MP, Martinez JA & Moreno-Aliaga MJ 2008 ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. Journal of Physiology and Biochemistry 64 61-66. (doi:10.1007/BF03168235)
35. Mencher SK & Wang LG 2005 Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clinical Pharmacology 5 3. (doi:10.1186/1472-6904-5-3)
36. 2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clinical Endocrinology 72 334-341. (doi:10.1111/j.1365-2265.2009.03658.x)
37. Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, Stocker C, Trayhurn P & Bing C 2010b Downregulation of zinc-{α}2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes. Journal of Endocrinology 204 165-172. (doi:10.1677/ JOE-09-0299)
38. Oriowo MA, Sennitt MV, Smith SA, Ruffolo RR Jr & Cawthorne MA 1994 The β-adrenoceptor selectivity profile of BRL 37344 in the pithed rat. Journal of Autonomic Pharmacology 14 337-344. (doi:10.1111/j.1474-8673.1994.tb00614.x)
39. 2-glycoprotein deficient mice. FEBS Letters 581 394-400. (doi:10.1016/j.febslet.2006.12.047)
40. Russell ST & Tisdale MJ 2002 Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. British Journal of Cancer 87 580-584. (doi:10.1038/sj.bjc.6600493)
41. 2-glycoprotein expression in adipose tissue in cancer cachexia. British Journal of Cancer 92 876-881. (doi:10.1038/sj. bjc.6602404)
42. 2-glycoprotein in ob/ob mice. Endocrinology 151 948-957. (doi:10.1210/ en.2009-0827)
43. 2-glycoprotein. Endocrinology 151 4696-4704. (doi:10.1210/en.2010-0532)
44. Russell ST & Tisdale MJ 2011 Studies on the antiobesity effect of zincα2-glycoprotein in the ob/ob mouse. International Journal of Obesity 35 345-354. (doi:10.1038/ijo.2010.150)
45. 2-glycoprotein (ZAG). Biochimica et Biophysica Acta 1821 590-599. (doi:10.1016/j.bbalip.2011. 12.003)
46. 2-glycoprotein (ZAG). Endocrinology 153 4696-4704. (doi:10.1210/en.2012-1260)
47. 3-adrenergic receptors in the action of a tumour lipid mobilizing factor. British Journal of Cancer 86 424-428. (doi:10.1038/sj.bjc.6600086)
48. 2-glycoprotein. Biochimica et Biophysica Acta 1636 59-68. (doi:10.1016/j.bbalip.2003. 12.004)
49. 2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Letters 212 71-81. (doi:10.1016/j.canlet.2004.03.021)
50. Sanders PM & Tisdale MJ 2004b Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage. British Journal of Cancer 90 1274-1278. (doi:10.1038/sj.bjc.6601669)
51. 2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. Journal of Clinical Endocrinology and Metabolism 94 4499-4507. (doi:10.1210/jc.2009-0758)
52. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Francon D, Alonso R et al. 2008 Stimulation of the β(3)-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33 574-587. (doi:10.1038/sj.npp.1301424)
53. Stocker CJ, Wargent E, O'Dowd J, Cornick C, Speakman JR, Arch JR & Cawthorne MA 2007 Prevention of diet-induced obesity and impaired glucose tolerance in rats following administration of leptin to their mothers. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 292 R1810-R1818. (doi:10.1152/ajpregu. 00676.2006)
54. Virtanen KA, Rouru J, Hanninen V, Savontaus E, Rouvari T, Teirmaa T, Koulu M & Huupponen R 1997 Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism. European Journal of Pharmacology 332 215-218. (doi:10.1016/S0014-2999(97) 01104-7)
55. 3-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology 374 385-398. (doi:10.1007/ s00210-006-0127-5)
56. Wargent E, Sennitt MV, Stocker C, Mayes AE, Brown L, O'Dowd J, Wang S, Einerhand AW, Mohede I, Arch JR et al. 2005 Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Lipids in Health and Disease 4 3. (doi:10.1186/ 1476-511X-4-3)
57. Wilson S, Arch JR & Thurlby PL 1984 Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sciences 35 1301-1309. (doi:10.1016/0024-3205(84)90102-4)
58. Yang YT & McElligott MA 1989 Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. Biochemical Journal 261 1-10.
59. Zaibi MS, Stocker CJ, O'Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM & Arch JR 2010 Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Letters 584 2381-2386. (doi:10.1016/j.febslet.2010.04.027)